Precision Therapies in Lung Squamous Cell Carcinoma
The status, timeline and source of this project. A free account opens every field.
Source: EU Funding & Tenders Portal
Lung squamous cell carcinoma (LSCC) represents one third of lung tumours; 550,000 cases are diagnosed annually worldwide (20% occur in Europe). Treatment options for this cancer type are still scarce. Identification of LSCC genetic drivers is thus an essential unmet need for developing novel therapies for this disease. In a stepwise multidisciplinary approach, we will determine if TNIK (Traf-2 and
- Status
- Closed
- Sector
- Education
- Location
- United Kingdom
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Precision Therapies in Lung Squamous Cell Carcinoma
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Lung squamous cell carcinoma (LSCC) represents one third of lung tumours; 550,000 cases are diagnosed annually worldwide (20% occur in Europe). Treatment options for this cancer type are still scarce. Identification of LSCC genetic drivers is thus an essential unmet need for developing novel therapies for this disease. In a stepwise multidisciplinary approach, we will determine if TNIK (Traf-2 and Nck-interacting kinase), a gene amplified in almost 40% of LSCC cases, constitutes a therapeutic target for the treatment of LSCC patients. Our preliminary data show that TNIK is overexpressed in LSCC cells, in which it has a pro-oncogenic role. Using proteomics approaches and functional assays, we will define the molecular mechanisms and critical signalling pathways that TNIK modulates to promote LSCC progression. In xenograft models we will confirm the contribution of TNIK to the studied phenotypes in vivo. We will analyse TNIK levels and activity (after identification of substrates) in patient samples, and will aim to validate TNIK as a target for therapeutic intervention using small molecule TNIK inhibitors in novel preclinical models: LSCC organoids and patient-derived xenografts. Finally, we will assess if increased TNIK expression can serve as a biomarker to select patients that would benefit from treatment with TNIK inhibitors. Our studies will increase our knowledge on LSCC biology and aim to find a precise treatment for this disease. This project will enable Dr P Torres-Ayuso to develop a wide range of new and transferable skills, and will allow him to broaden his technical, mentoring, management and communication skills. He will benefit from the high calibre of the Cancer Research UK Manchester Institute, and the expertise of his supervisor (Dr J Brognard) who will aid in his development as a young scientist. This project will thus enable the Fellow to achieve his long-term objective of obtaining a leadership position in a competitive European Institute. |
Location
Country | United Kingdom (UK) |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Education |
Article published date | 2026-01-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Education projects in United Kingdom
- RAF Fairford
- Fish Food & Business Park, Fleetwood
- Coca Cola Bottling Plant, Wakefield, England
- Michael Uren Biomedical Engineering Research Hub, London
- Core Technology Facility, University Of Manchester, Manchester
- Pukka Pies
- The Francis Crick Institute, London
- The Pears Building, Royal Free Hospital, London, UK
